Assessment of aztreonam-avibactam (ATM-AVI) CLSI 30/20 ?g disk content against carbapenemase-producing Enterobacterales (CPEs) Navegación de entradas Dynamic Trends in Serotypes and Antimicrobial Resistance of S. pneumoniae in ArgentinePediatrics: Insights from 2018 to 2022. New insights in therapeutic options against difficult-to-threat Pseudomonas aeruginosa (DTR-PA): in vitro activity of aztreonam in combination with avibactam, relebactam and in double ?-lactams combinations with ceftazidime/avibactam and imipenem/relebactam.